相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000-2009
K. I. Kaitin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
TRIAL WATCH Phase III and submission failures: 2007-2010
John Arrowsmith
NATURE REVIEWS DRUG DISCOVERY (2011)
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
J. A. DiMasi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
SPENDING ON NEW DRUG DEVELOPMENT
Christopher Paul Adams et al.
HEALTH ECONOMICS (2010)
Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support the Rhetoric?
Anne Mason et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
Frank Dieterle et al.
NATURE BIOTECHNOLOGY (2010)
Development trends for human monoclonal antibody therapeutics
Aaron L. Nelson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Do molecularly targeted agents in oncology have reduced attrition rates?
Ian Walker et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The price of innovation: new estimates of drug development costs
JA DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2003)
分享论文
